Form 4: TriSalus Life Sciences CEO Increases Stake in Company
SEC Form 4 Filing
Mary T. Szela, CEO and President of TriSalus Life Sciences, recently purchased additional shares of the company's common stock.
Summary
- On September 12 and 13, 2024, Mary T. Szela, the CEO and President of TriSalus Life Sciences, acquired shares of the company's common stock.
- On September 12, she purchased 7,520 shares at a weighted average price of $5.20, with prices ranging from $5.05 to $5.32.
- On September 13, she made two purchases: 1,295 shares at $4.83 and 6,000 shares at $5.00.
- Following these transactions, Ms. Szela directly owns 384,677 shares of TriSalus Life Sciences common stock.
Sentiment
Score: 7
Explanation: The sentiment is moderately positive due to the CEO's increased investment in the company, which signals confidence. However, it's a single event and doesn't provide a comprehensive view of the company's overall health.
Positives
- The CEO's purchase of additional shares could be interpreted as a positive signal about her confidence in the company's future prospects.
Industry Context
Insider buying is often seen as a positive sign, suggesting that a company's leadership believes the stock is undervalued.
Stakeholder Impact
- Shareholders may view the CEO's stock purchase as a positive signal.
Key Dates
| Date | Description |
|---|---|
| 09/12/2024 | CEO purchased 7,520 shares of common stock at a weighted average price of $5.20. |
| 09/13/2024 | CEO purchased 1,295 shares at $4.83 and 6,000 shares at $5.00. |
| 09/13/2024 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.